Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab
Authors:
- Jürgen BraunJBJürgen Braun
- Atul DeodharADAtul Deodhar
- Robert InmanRIRobert Inman
Open Access
- 30 July 2009
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 61 (8) , 1032-1036
Abstract
Objective: Anemia is a common complication in patients with inflammatory diseases such as ankylosing spondylitis (AS). This post hoc analysis of a large, randomized, placebo‐controlled trial examined the effect of infliximab on hemoglobin levels, physical function, and fatigue in patients with AS.Methods: Patients received infliximab 5 mg/kg (n = 188) or placebo (n = 68) at weeks 0, 2, 6, 12, and 18. Hemoglobin, interleukin‐6 (IL‐6), and C‐reactive protein (CRP) levels, fatigue (visual analog scale [VAS]), physical function (Bath Ankylosing Spondylitis Functional Index [BASFI]), and disease activity were evaluated at baseline and week 24. Anemia was defined as a hemoglobin level P = 0.0155). Infliximab‐treated patients had significant improvements in mean hemoglobin concentration (0.7 gm/dl versus −0.3 gm/dl), BASFI score (−2.1 versus −0.2), and fatigue VAS score (−2.4 versus −0.4) compared with placebo patients (P < 0.001). Multiple regression analyses showed that improvements in hemoglobin level were significantly and independently associated with improvements in physical function and fatigue. Infliximab‐treated patients with elevated CRP or IL‐6 levels at baseline were more likely than those with low levels to have improvement in hemoglobin levels.Conclusion: Infliximab treatment significantly decreased the proportion of AS patients with anemia and improved hemoglobin levels compared with placebo. Improvement in hemoglobin level was independently associated with improvements in physical function and fatigue.Keywords
This publication has 14 references indexed in Scilit:
- Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor β in three more advanced casesAnnals of the Rheumatic Diseases, 2006
- ASAS/EULAR recommendations for the management of ankylosing spondylitisAnnals of the Rheumatic Diseases, 2006
- Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectumJoint Bone Spine, 2005
- Anemia of inflammation: the hepcidin linkCurrent Opinion in Hematology, 2005
- Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)Arthritis & Rheumatism, 2005
- IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidinJournal of Clinical Investigation, 2004
- Molecular and cellular biology of new bone formation: insights into the ankylosis of ankylosing spondylitisCurrent Opinion in Rheumatology, 2003
- Report on the Second International Enthesitis WorkshopArthritis & Rheumatism, 2003
- Role of Cytokines in the Pathogenesis of Anemia of Chronic Disease in Rheumatoid ArthritisClinical Immunology, 1999
- Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritisEuropean Journal of Clinical Investigation, 1992